国产精品视频观看,又大又粗有色,琪琪吊操人妻日韩精品,欧美 国产 日韩成人

服務熱線

15021010459
技術文章
當前位置:主頁 > 技術文章 > Ariad抗癌藥Iclusig重返市場

Ariad抗癌藥Iclusig重返市場

更新時間:2014-01-20 點擊次數:1709

    去年Ariad Pharmaceuticals公司業(yè)績由于主打抗癌藥物Iclusig被緊急下架而遭受重創(chuàng)。公司一度陷入困境并將其在美國的員工裁員160人,約占美 國分部總員工數的40%,以節(jié)省開支。不過現(xiàn)在Ariad Pharmaceuticals公司迎來一絲曙光。公司已經著手將Iclusig重新推向市場。此次Ariad將把Iclusig的適用癥范圍縮小,并在 藥物包裝上標明可能出現(xiàn)的副作用如心臟病、血液凝塊等。不過由于Iclusig適用范圍變小,公司的收入可能也會大受影響。為解決這一問題公司計劃申請重 啟此前被FDA下令暫停的關于Iclusig治療慢性白血病的研究計劃以達到亡羊補牢的作用。

    不過Ariad Pharmaceuticals公司的這一系列舉措能否獲得預期效果還需要等待公司2014年*季度財報公布后才能知曉。

詳細英文報道:

    Last year, Ariad Pharmaceuticals ($ARIA) watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

    The drug is now indicated for a smaller group of leukemia patients than before, and it carries a serious boxed warning about the risk of clotting and heart failure that got it pulled from shelves in the fall. But it is for sale, and that puts Ariad in a better place than many predicted at its nadir.

    "We are back on track," CEO Harvey Berger told Bloomberg last month. "We'll enter 2014 largely where we were as we started off the fall in September."

    Of course, that's not entirely the case. Losing more than half of its value forced Ariad to considerably thin its ranks, laying off 40% of its U.S. workforce--or 160 employees--in an effort to save $26 million. Now the company plans to gradually ramp up stateside sales with the help of specialty pharmacy Biologics, Inc., first looking to transition the case-by-case patients who were still using the drug during its marketing hiatus.

    And the company has a long way to go on the R&D side. When the storm over Iclusig began, Ariad was in the process of testing the drug in a broader population, but an FDA-imposed clinical hold led the company to discontinue a Phase III study on patients with newly diagnosed chronic myeloid leukemia and put the brakes on a fleet of Phase II studies designed to expand the drug's market. Berger has said that Ariad is yet to decide just how to move forward with its paused programs.

    Still, the biotech is undeniably sitting prettier than it was just two months ago, and its next big test will come when Q1 sales figures roll in.——(華雅干細胞整理報道)

2025 版權所有 © 重慶市華雅干細胞技術有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術支持:化工儀器網

地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

重慶市華雅干細胞技術有限公司主要經營干細胞研究 干細胞治療產品 生物試劑 實驗耗材 藥物研發(fā)等產品。

關注我們

服務熱線

400-021-2200

掃一掃,關注我們

国产精品久久久久无碼AV| 亚洲一区二区三区下载| 日本精品久久久久久久久免费| 国产欧美一区二区精品97| 汉中市| 欧美日韩国产中文字幕| 欧美一级a一级a爱片免费| 少久久久| 精品一区二区三区无码中文视频| 精品综合在线免费视频| 九九国产99精品| 久久人人妻人人做人人玩精品| 黄色电影国产精品久久| 凹凸精品在线| 91精品麻豆人妻一区二区| 亚洲一牛影视| 亚洲 国产 不卡| 亚洲AV无码精品色午夜蛋壳| 欧美日韩成人午夜免费| 呦呦成人| 99久久人妻无码| 国产亚洲精品无码成人百度| 日本 成人 婷婷在线| 韩国一级毛片无码二专区| 女人毛片a级毛片免费视频| 久久免费看毛片| 亚洲日韩国产精品乱| 中文字幕97在线| 日韩宗合| 亚洲成a人片在线观看精品| 久久精品无码一区二区日韩AⅤ| 强奸不卡av| 中文字幕一区日韩精品欧美| 亚洲第一无码专区天堂| 999久久久国产精免费观| 黄片无码久久久久久| 福利一区福利二区| 欧美3a视频免费看| 亚洲欧美日韩久久久久| 国产成人综合久久精品推最新| 国产毛片一区|